Research programme: inflammatory and respiratory disease therapeutics - Almirall/BioFocus
Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Almirall S.A.; BioFocus DPI
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Respiratory tract disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in United Kingdom
- 16 Jul 2016 No recent reports of development identified for research development in Respiratory-tract-disorders in United Kingdom
- 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories